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Proteolysis of the extracellular matrix components plays a crucial role in the regulation of the cellular and physiological processes, and
different pathologies have been associated with the loss or gain of function of proteolytic enzymes. DESC1 (differentially expressed in
squamous cell carcinoma gene 1), a member of the TTSP (type II transmembrane serine protease) family of serine proteases, is an
epithelial-specific enzyme that has been found downregulated in squamous cell carcinoma of the head and neck region. We describe
new properties of DESC1 suggesting that this protease may be involved in the progression of some type of tumours. Thus, this
enzyme hydrolyses some extracellular matrix components, such as fibronectin, gelatin or fibrinogen. Moreover, Madin–Darby canine
kidney (MDCK) cells expressing exogenous human DESC1 acquire properties associated with tumour growth such as enhanced
motility and an increase of tubular forms in a 3D collagen lattice following HGF treatment. Finally, we generated polyclonal anti-
DESC1 antibodies and immunohistochemical analysis in tissues different from head and neck region indicated that this protease was
overexpressed in tumours of diverse origins. Taken together, our results suggest that DESC1 could be considered as a potential
therapeutic target in some type of tumours.
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Pericellular proteolysis is a crucial biological event: membrane-
associated proteolytic enzymes are involved in dynamic rearrange-
ments in cell–cell and cell–matrix interactions and deregulation
of these activities underlies different pathologies, including cancer
(Freije et al, 2003). In fact, the uncontrolled degradation of the
extracellular matrix allows the tumour cells to invade surrounding
tissues and spread throughout the body. Thus, it is easy to
understand that the identification and further characterisation of
the proteolytic systems constitute an important challenge for
biomedical research, since it may help to identify accurate
molecular markers to detect the metastatic disease (Overall and
Lopez-Otin, 2002).
The TTSP (type II transmembrane serine proteases) constitute a
family of membrane-anchored serine proteases of growing interest
since many members have been found widely deregulated during
tumour development and progression (Netzel-Arnett et al, 2003).
These proteases are structurally complex enzymes containing the
catalytic domain at the carboxy terminal region. This domain
possesses three highly conserved residues (His, Asp and Ser),
which form the catalytic triad of the enzyme. The amino terminal
region includes the transmembrane region and an activation
domain to switch the protein to its active form. Between these two
regions, a variable number of potential protein–protein inter-
action modular domains can be found. More than 17 members in
humans and 20 TTSP genes in mice have been identified at present
(Szabo et al, 2005). Although the specific role of most of these
enzymes remains unresolved, available information indicates that
the TTSP are involved in a variety of key biological functions.
Thus, matriptase is an essential enzyme for postnatal survival,
epidermal barrier function, hair follicle development and thymic
homeostasis in mice (List et al, 2002, 2006); HAT (human airway
trypsin-like protease) has been proposed to play a role in host
immune defence (Yamaoka et al, 1998); corin regulates blood
pressure by activating the cardiac hormone pro-ANP (Yan et al,
2000); and TMPRSS3 has been suggested to be involved in inner
ear development (Guipponi et al, 2002). Likewise, the role of the
TTSP in tumour growth, cancer invasion and metastasis processes
are being increasingly documented for proteases such as
matriptase (List et al, 2005), matriptase-2 (Velasco et al, 2002)
and hepsin (Hobson et al, 2004; Klezovitch et al, 2004).
The HAT/DESC constitutes a phylogenetically related subfamily
of TTSP (Netzel-Arnett et al, 2003) with five DESC1 (differentially
expressed in squamous cell carcinoma gene 1)-like genes clustered
within a region in the chromosome 4q (Behrens et al, 2004;
Hobson et al, 2004). DESC1 was identified through the reduced
levels of associated mRNA present in tumours from diverse sites in
the head and neck region when compared with corresponding
normal tissue (Lang and Schuller, 2001). Recently, the protein has
been reported to be downregulated in tissues from the orophar-
yngeal cavity during the squamous cell carcinoma progression and
upregulated during normal epithelial differentiation (Sedghizadeh
et al, 2006).
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sOur interest in genes differentially expressed in head and neck
carcinomas has directed our attention to DESC1. In this report we
describe new insights about the biochemical and functional
properties of this protease indicating that this enzyme could be
involved in tumour progression. Thus, this protease can hydrolyse
different extracellular matrix components and also can activate
pro-uPA. Likewise, different assays using Madin–Darby canine
kidney (MDCK) cells stably transfected with DESC1 full-length
cDNA showed that this enzyme enhances cell motility. Moreover,
these cells form long extensions when they are grown in 3D
collagen lattice, which represents a partial epithelial–mesenchymal
transition (O’Brien et al, 2002). Finally, the generation of
antibodies towards its catalytic domain has allowed us to find
that DESC1 is overexpressed in a variety of previously untested
tumours of different origins.
MATERIALS AND METHODS
Molecular cloning of human DESC1
The DESC1 cDNA sequence (GenBank accesion number AF064819)
was used as query to carry out a search in the NCBI human
Expression Sequence Tag (EST) database (www. ncbi.nlm.nih.gov/
Blast/Blast.cgi). An EST sequence from a skin cDNA library,
BG697702, was identified and purchased from the Geneservice Ltd
(Cambridge, UK). This EST served as template for a PCR
amplification of the human DESC1 full-length cDNA using specific
primers. The amplification product was cloned into the EcoRV site
of the mammalian vector pcDNA3 containing a haemagglutinin
(HA) epitope at the C terminus to give a pcDNA-HA-DESC1
vector. The identity of the sequence was confirmed by automated
nucleotide sequencing.
Production and purification of recombinant catalytic
domain DESC1, generation of polyclonal antibodies and
Western blot analysis
A 695-bp fragment of the DESC1 cDNA encoding the entire serine
protease domain was generated by PCR amplification using the
EST BG697702 as template and the specific oligonucleotides desc3F
(50-ATCGTTGGTGGGACAGAAGTAG-30) and desc1R (50-GATAC
CAGTTTTTGAAGTAATCCAG-30). PCR amplification conditions,
cloning in pGEX-3X vector, and expression and purification of
DESC1 catalytic domain fused to GST were carried out as
described to characterise matriptase-2 (Velasco et al, 2002), with
minor modifications. The resulting expression vector (pGEX-3X-
DESC1) was transformed into BL21(DE3)pLysS competent E. coli
cells, and expression was induced by the addition of isopropyl-
1-thio-b-D-galactopyranoside (final concentration, 0.5mM) followed
by further incubation for 4–6h at 301C. The cells were collected by
centrifugation, washed and resuspended in 0.05 volumes of PBS.
Finally, the cells were lysed by sonication and centrifuged at
20000g for 20min at 41C. The soluble extract was loaded on a
glutathione-Sepharose 4B column (GE Healthcare, Uppsala,
Sweden), and the glutathione S-transferase GST-DESC1 fusion
protein eluted with glutathione elution buffer (10-mM reduced
glutathione in 50mM Tris–HCl, pH 8.0), following the manufac-
turer’s instructions. Finally, the purified GST-DESC1 fusion
protein was used for enzymatic assays. GST alone was also
produced using same experimental procedures to be used as a
control in further assays. Recombinant DESC1 catalytic domain
was likewise employed to generate polyclonal antibodies against
DESC1, following the same strategy used to generate anti-
polyserase-1 antibodies (Cal et al, 2003). For Western blot analysis,
proteins were separated on SDS–PAGE gels, blotted onto
nitrocellulose membranes and incubated following standard
procedures.
Gelatin zymography
A 0.5mg of GST or GST-DESC1 were mixed with SDS sample buffer
in absence of reducting agents. Then, and without boiling, the
samples were subjected to electrophoresis in a 12% acrylamide gel
containing 0.2% gelatine. Gel was run at 10mA, washed in 2.5%
Triton X-100 for 3h and incubated at 371C for 16h in 20mM Tris–
HCl pH 7.4, and 5mM CaCl2. After incubation, the gel was stained
with Coomassie Brilliant Blue R-250, and destained in 30%
methanol and 10% acetic acid. Gelatinolyc activities were detected
as clear bands in the blue background. As positive control 5mlo f
HT1080 conditioned medium were added to one of the lanes
(Stanton et al, 1998).
Enzymatic assays
To detect the enzymatic activity of the purified enzyme,
recombinant DESC1 was incubated with 5mg of different proteins
including type I laminin, type I gelatin, fibronectin and fibrinogen
or 1mg of pro-uPA. Reactions were carried out and visualised as
described in Velasco et al (2002). For the inhibition assays,
recombinant protein was previously incubated for 30min at 371C
with 20mM AEBSF, 0.2mM TPCK, 2.5mM EDTA or 35mM E64, and
the subsequent reactions were performed using fibrinogen as
substrate. Synthetic peptides Boc-Gln-Gly-Arg-AMC and Boc-Gln-
Ala-Arg-AMC were likewise used to detect enzymatic activity, and
assays were carried out using 10mM of substrate and 40ng of
DESC1. Inhibition was likewise tested preincubating the enzyme
for 30min at 371C with 2.5mM EDTA; 20, 200 and 500mM AEBSF;
35mM E-64; 20nM antitrypsin or 20nM antichymotrypsin. Initial
velocities were calculated using the analysis package FL WinLab
2.01 (PerkinElmer Life Sciences, Waltham, MA, USA), and data
were fitted to the Michaelis–Menten equation using GraFit version
4.0 (Erithacus, Surrey, UK). Purified GST was used as a negative
control under the same experimental conditions.
Cell culture conditions, transfection and
immunofluorescence
MDCK cell line was routinely maintained in DMEM media
supplemented and 10% fetal bovine serum (FBS) (Invitrogen,
Karlsruhe, Germany). MDCK clones expressing recombinant
DESC1 (MDCK/DESC1 cells) and MDCK transfected with an
empty vector (control cells) were obtained by transfection using
the LipofectAMINE reagent (Invitrogen). Stable transfection in
MDCK cells was carried out in DMEM medium containing
800mgml
 1 of geneticin. To detect recombinant DESC1, cells were
fixed with 4% paraformaldehyde in phosphate-buffered saline, and
blocked with 15% of FBS. Then, the slides were incubated for 2h
with a primary anti-HA (Roche, Basel, Switzerland) or anti-DESC1
antibody, followed by 2h of incubation with a secondary
fluorescein-conjugated sheep anti-mouse antibody (GE Health-
care) or a Texas Red-conjugated donkey anti-rabbit secondary
antibody (GE Healthcare), respectively. In all samples, 40,60-
diamino-2-phenylindole hydrochloride was added at 100ngml
 1
to visualise DNA in the cell nucleus. Images were obtained using a
fluorescence microscopy Axiovert 200 (Zeiss, Jena, Germany) and
a digital camera. MDCK cells transfected with a vector containing
the polyserase-1 cDNA (Cal et al, 2003) were used as negative
control.
Scrape-wound migration assay and matrigel invasion assay
Monolayers of MDCK/DESC1 cells or control cells were scraped
with a pipette tip in a single stripe. The wounded cultures were
incubated at 371C and cells migrating into the scraped area were
imaged at different times. Tumour cell invasion assay was
performed in cell culture chambers coated with matrigel (BD
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sBiosciences, San Jose, CA, USA) following manufacturer instruc-
tions. In brief, MDCK/DESC1 transfected cells and control cells
were seeded (5 10
4 cellswell
 1) in DMEM medium containing
5% BSA and 50ngml
 1 HGF. A 10% FBS was additionally included
in the lower chambers to act as a chemoattractant. After 48h of
incubation, the cells on the lower membrane surface were fixed
and stained with 0.5% crystal violet in 10% methanol. Randomly
selected microscopic fields (magnification  20) were imaged to
calculate the average number of occupied pores per microscopic
field. Data are expressed as mean7s.e.m. Differences in value
distribution were statistically validated using the two-tailed t-test
for unpaired data. Statistical analyses were performed using the
program GraphPad Prism 3 for Windows. Difference was
considered to be significant at values lower than Po0.05.
Analysis of morphological changes in a 3D collagen lattice
MDCK/DESC1 cells or control cells were assayed to evaluate their
ability to form tubular structures within a 3D Collagen Cell Culture
System (Chemicon International, Temecula, CA, USA), following
manufacturer instructions. Briefly, 1 10
3 cells were mixed with a
neutralised chilled collagen solution, dispensed into 96-well plates
and incubated at 371C until gelification. Culture medium contain-
ing 3% FBS and HGF (30ngml
 1) or without HGF (control) was
added to the wells and renewed every day for 7 days. Cultures were
photographed after 7 days under phase contrast using an inverted
microscope. To semiquantify the formation of tubular structures,
15 microscopic fields were randomly selected per experimental
condition. Then, the number of tube structures was determined,
and their length was also measured by using image analysis
software.
Immunohistochemistry
Human tissues were obtained as formalin-fixed, paraffin-
embedded tissue sections from the archives of the tumour bank
from the Hospital Universitario Central de Asturias (HUCA, Oviedo,
Asturias, Spain). Tissue arrays were likewise used to evaluate
DESC1 expression according to the histological type of cancer.
After dewaxing and rehydrating, samples were blocked in 15% goat
serum and then incubated overnight with anti-DESC1 antibody
(1:150). Then, sections were incubated with an EnVision System
labelled polymer-HRP anti-rabbit (DAKO, Glostrup, Denmark),
and the staining was completed by incubation with diaminobenzi-
dine colorimetric reagent (DAKO), followed by counterstaining
with hematoxylin. Finally, the slides were dehydrated and
mounted. Controls included samples that were incubated with a
preimmune serum.
RESULTS
Production of the recombinant DESC1 catalytic domain
and generation of polyclonal antibodies
Molecular cloning of the human DESC1 full-length cDNA was
carried out by PCR amplification using EST BG697702 as template.
The amplified product was 1269-bp long and contained the open
reading frame reported previously (Lang and Schuller, 2001). The
catalytic domain of this protein was expressed independently from
the rest of the molecule following a strategy previously used to
analyse other members of this family of proteases (Velasco et al,
2002). To this end, a 695-bp fragment coding for this region was
PCR amplified and subcloned into the pGEX-3X vector generating
the plasmid pGEX-3X-DESC1, which allows the expression of this
catalytic domain fused to the glutathione-S-transferase. This
region contains 231 amino acids (25.4KDa), starting at the
Ile191 after the putative proteolytic activation site (Arg190) within
the conserved R-IVGG motif of this type of serine proteases
(Netzel-Arnett et al, 2003). A 51.4kDa band corresponding to the
combined molecular masses of GST (26kDa) and DESC1
(25.4kDa) was detected by SDS–PAGE (Figure 1A). This fusion
protein was purified by affinity chromatography on a glutathione-
Sepharose 4B column (Figure 1A). DESC1 was not released from
the GST with Factor Xa to avoid any minor contamination of this
protease in the subsequent analysis of DESC1 activity. However,
DESC1 was spontaneously released from the GST probably as a
consequence of an autocatalytic processing during the course of
the different assays (Figure 1A). This effect has been described for
other TTSPs such as matriptase (Takeuchi et al, 1999), matriptase-
2 (Velasco et al, 2002), matriptase-3 (Szabo et al, 2005), TMPRSS2
(Afar et al, 2001) and TMPRSS3 (Guipponi et al, 2002).
The DESC1 protein fused to GST was likewise used to generate
rabbit polyclonal antibodies against human DESC1. The specificity
of these antibodies was tested during the protein purification
process by Western blot (Figure 1B). As expected from an
autoactivation process, immunoreactive bands of 51.4, 26 and
25.4kDa were clearly visible, corresponding to the fusion protein
(GSTþDESC1), and the released GST and DESC1, respectively. A
0.5mg of trypsin was added to the gel to be used as negative
control. The produced antibodies also recognise the mix of GST
and DESC1 after purification by affinity chromatography. This
result reveals the ability of the generated antibody to recognise
DESC1.
DESC1 is a catalytically active serine protease that cleaves
protein substrates
Enzymatic activity of DESC1 was demonstrated through different
assays. Thus, a gelatine zymogram indicated that this serine
protease displayed a prominent gelatinolytic activity. By contrast,
the GST alone, expressed and purified in parallel to be used as a
negative control, did not show any activity (Figure 2A). Then,
DESC1 recombinant protein was incubated with different protein
substrates, including extracellular matrix protein components, and
the products of the reactions were visualised by SDS–PAGE gels.
As Figure 2A shows, DESC1 hydrolyses fibronectin, gelatin, pro-
UPA, but not laminin. The enzyme may likewise hydrolyse
AB
Unstransformed
pGEX-3X-DESC1
DESC1
M
20
25
37
50
75
25
37
50
DESC1
pGEX-3X-DESC1
pGEX-3X
Trypsin
20
Figure 1 Production of recombinant DESC1. (A) Untransformed
BL21(DE3)pLysE E. coli cells (lane 2) and cells transformed with pGEX-
3X-DESC1 after IPTG induction (lane 3) or purified DESC1 (lane 4) were
analysed by SDS–PAGE. The sizes of molecular weight marker (kDa) are
indicated on the left (Lane 1, M). DESC1 fused to GST is indicated with a
thin arrow. Position for DESC1 released from GST is indicated with a thick
arrow. (B) Western blot analysis of the proteins using the anti-DESC1
antibodies generated in this work. Fused GSTþDESC1 protein (50.4kDa)
and released GST (26kDa) and DESC1 (25.4kDa) are indicated with
arrows (lane 1). The generated antibodies detect GST expressed alone
(lane 2), but not trypsin (lane 3). Lane 4, purified products eluted from a
glutathione-Sepharose 4B column.
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sfibrinogen (Figure 2B). However, proteolytic activity on these
substrates was not detected when incubated with GST alone
(Figure 2A and B). These results suggest a potential role for DESC1
in the degradation and/or remodelling of the extracellular matrix
ECM. Furthermore, the cleavage products obtained from DESC1
incubation with the single-chain pro-uPA (Figure 2A) resembled
the size of the two chain forms (20 and 33kDa) of the
enzymatically active uPA capable of interacting with the uPA
receptor, a system which is known to play a critical role in cancer
progression. Preincubation of DESC1 with serine proteases
inhibitors such as AEBSF or TPCK produces a considerable
reduction in the g-chain of fibrinogen cleavage (Figure 2B). By
contrast, this effect was not observed when the preincubation was
carried out with inhibitors for other types of proteases like EDTA
and E64 (Figure 2B).
We have also examined the ability of DESC1 to degrade peptide
substrates (Figure 2C). The predicted preferential cleavage for other
TTSPs at amino acid residues with positively charged side chains
was tested for DESC1 using two synthetic AMC-coupled peptides
with Arg residues as P1 site. The results indicated that DESC1 was
able to cleave Boc-Gln-Gly-Arg-AMC more efficiently than Boc-
Gln-Ala-Arg-AMC (data not shown), with a Km of 134mM and Vmax
of 3 10
 4mMs
 1. The proteolytic activity of DESC1 using the first
peptide substrate was inhibited by preincubation with the serine
proteinase inhibitor AEBSF (above 80% inhibition at 500mM).
These results confirm the serine protease nature of DESC1.
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Figure 2 Analysis of enzymatic properties of DESC1. (A) Gelatin zymography: purified DESC1 has gelatinolytic activity. Purified GST was used as negative
control and 5ml of the conditioned medium of the cell line HT1080 was used as positive control. ProMMP9 and MMP9, and ProMMP2 and MMP2
gelatinolytic activities are indicated with an arrow. Fibronectin, type I gelatin, laminin and pro-uPA were incubated alone ( ) or in presence of purified GST
or DESC1. Molecular weight markers (M, kDa) are shown on the left and for pro-uPA, on the right. (B) Fibrinogen was also incubated alone ( )o ri n
presence of GST (lane 2) or DESC1 (lane 3). Preincubation for 30min at 371C with 100mM AEBSF (lane 4), 0.2mM TPCK (lane 5), 2.5mM EDTA (lane 6) or
10mM E64 (lane 7) was carried out before incubation with the substrate. GST and DESC1 positions are indicated on the right. (C) Inhibition assay using the
synthetic fluorescent peptide Boc-Gln-Gly-Arg-AMC as susbstrate. Recombinant DESC1 was preincubated in the presence or absence of the protease
inhibitors as indicated in Material and Methods. ( ) indicates absence of inhibitor.
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sMembrane localisation and effect of DESC1 expression on
motility of MDCK cells
MDCK cells were stably transfected with DESC1 cDNA (MDCK/
DESC1 cells) to examine the possible contribution of this protease
to cellular invasiveness. Expression of exogenous DESC1 was
confirmed by immunostaining using the generated anti-DESC1
antibody and an anti-HA antibody (Figure 3A). MDCK cells
transfected with a vector containing the cDNA encoding for
polyserase-1 was used as control. In all cases, the samples were not
permeabilised to detect the presumably extracellular catalytic
domain. Two positive clones were selected for further analysis and
results were equivalent in both cases. These assays were carried out
using two different approaches. First, these clones were grown to
confluence to carry out a scrape-wound migration assay. After
in vitro ‘wounding’ of the cell monolayers, the cultures allowed to
grow and wound closures were visualised at different times. As can
be seen in Figure 3B, MDCK/DESC1 migrated to nearly cover the
wound site within 8h. By contrast, wound closure was incomplete
after the same time interval in control cells (MDCK cells stably
transfected with an empty vector), remaining almost intact after
24h. These data suggest that DESC1 may be involved in migration
and motility properties of these cells.
The second approach consisted in analysing cell behaviour in a
matrigel invasion assay. In this case, we used invasion chambers to
evaluate the ability of MDCK/DESC1 cells to degrade matrigel.
After 48h of incubation and 10% FBS used as chemoattractant, the
migratory cells were stained and the number of pores occupied in
randomly selected 20 microscopic fields were counted and
averaged (Figure 3C). A significant difference was observed
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Figure 3 Membrane localisation and effect of DESC1 expression on MDCK cells motility. (A) Immunocytochemical detection of recombinant DESC1
expression in MDCK cells. The images were captured by fluorescence microscopy of MDCK cells transfected with pcDNA-HA-DESC1 vector or with the
same pcDNA3-HA plasmid containing the cDNA for polyserase-1. Immunofluorescent detection of anti-HA antibodies was carried out with a fluorescein-
conjugated anti-mouse antibody, and detection of anti-DESC1 antibodies with a Texas Red-conjugated anti-rabbit antibody. Result shows the membrane
localisation of DESC1. (B) Wound closure assay. Scrape wounds were made in confluent monolayers of cells stably transfected with vector containing
DESC1 or control vector. Cell layers were imaged at the indicated times. (C) Matrigel invasion assay. Invasion capacity of MDCK/DESC1 cells and control
transfectants were analysed by a Matrigel invasion assay after 48h of incubation. Number of occluded pores by the cells and by the control cells transfected
were counted and represented on the right (*Po0.0001). N indicates the number of microscopic fields analysed.
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sbetween the levels of migration of the MDCK/DESC1 when
compared to the MDCK cells transfected with the empty vector.
Likewise, MDCK/DESC1 cells not only could extravasate the matrix
but they also showed a branched and more elongated morphology
than control cells. This tendency was also apparent at 24h of
incubation and also when lowering the chemoattractant concen-
tration to 2% (not shown).
MDCK cells expressing DESC1 form cysts that display long
extensions in a 3D collagen lattice
MDCK cells have been reported to form cysts and develop
branching tubules following HGF stimulation when they are grown
embedded in collagen gel network (Ridley et al, 1995). We wanted
to evaluate the ability of DESC1 to induce these effects in MDCK
cells. To test this, MDCK/DESC1 or control cells were mixed with a
collagen gel and allowed to grow. These assays were carried out
with or without HGF treatment and the cultured cells were imaged
after 7 days. As can be seen in Figure 4A, MDCK/DESC1 cells
form cysts from which surface-long branching extensions
are clearly detectable following HGF stimulation. In terms of
number of tube structures, DESC1 expression induces the
formation of more tubes than control cells (average of 6.5 vs 3.5,
respectively). However, the difference is considerably higher in
terms of tube lengths (60.8mm vs 10.5mm). Moreover, the
formation of these extensions clearly diminished with the presence
50mM of the serine proteinase inhibitor AEBSF (Figure 4A and B).
These data would indicate that DESC1 expression enhances the
capacity of MDCK to invade a collagen matrix following HGF
stimulation.
Analysis of DESC1 expression in normal and tumoral
human tissues
DESC1 expression in oropharyngeal cavity correlates directly with
keratinocyte differentiation and inversely with squamous cell
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Figure 4 (A) HGF-stimulated MDCK/DESC1 cells embebbed in collagen gel form tubular structures. MDCK cell clones stably transfected with control
vector or expressing DESC1 were cultured in a type I collagen matrix for 7 days in presence (þ) or in absence ( )o f3 0n gm l
 1 of HGF, and in the
presence (þ) or absence ( )o f5 0mM of AEBSF. The branching extensions formed by MDCK/DESC1 cells are indicated by arrows. (B) Quantification of
the number and length of tubular structures of 15 randomly selected microscopic fields following HGF stimulation.
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scarcinoma progression (Sedghizadeh et al, 2006). However, our
data suggest that DESC1 could be implicated in the development
and/or progression of some type of tumours. These facts prompted
us to extend the study of DESC1 expression to different type of
tissues including kidney, liver, brain and breast. This study was
carried out using the antibodies generated in this work and, to
determine optimal antibody dilutions, we first employed a normal
larynx tissue sample that showed an immunostaining of the
epithelial component (Figure 5A). This signal was absent when the
sample was treated with preimmune serum (Figure 5A). Then, we
employed paraffin-embedded tissue and tissue arrays that included
specimens of normal and squamous carcinoma, adenocarcinomas
and other tumours of different histological type. Figure 5Ba–d
shows DESC1 expression in normal and tumoral kidney. Normal
tubule epithelial cells showed intense expression (Figure 5Ba;
arrow). Inflammation and atrophy represented in Figure 5Bb and c
(arrowhead) correlate with a dramatic loss of expression that is
also apparent in the derived clear cell tumour (Figure 5Bc, arrow).
Brain
Breast Liver
b a
B
A
tumour
inflammation
and atrophy
Tubules
Kidney
d
c
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b
h
g
f
e
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i
Figure 5 DESC1 expression in kidney, liver, brain and breast normal and tumour tissues. (A) (a) Immunostaining of the epithelial component of a larynx
tissue sample using the antibody generated in this work. (b) Immunostaining performed with a preimmune control serum does not show this pattern. (B)
(a–d) IHC in kidney. (a) Normal kidney showing DESC1 expression in tubules (arrow). (b) Reactive tubules show positive expression (arrow), the proximal
inflammated and atrophical region is negative (arrowhead in b and c), and the derived well-differentiated clear cell tumour in (c) is negative (see arrow). (d)
Sample from a tissue array slide showing positivity in a poorly differentiated renal clear cell tumour. Note the negativity in the stroma. (e–f) IHC in liver. (e)
Liver tissue showing intense signal in the pericentral hepatocytes. (f) Renal invasive hepatocarcinoma corresponding to the same specimen as in (e). Staining
diminishes in the nodal satellite (arrow) that compresses some positive normal hepatocytes (arrowhead). (g–h) IHC of the brain. (g) Leptomeninges (dura
mater) showing negative expression of DESC1. (h) Atypical meningioma showing positivity. (i–l) IHC of breast. (i) Reactive benign breast tissue showing
slight positivity surrounding a negative duct. (j) Negative immunostaining in a ductal micropapilar breast tumour. (k) Positivity in a ductal breast carcinoma. (l)
Positivity in a lobular breast carcinoma. Magnification was 20  and counterstaining was with haematoxylin.
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sWe tested two negative renal tumours versus six positive cases (see
example in Figure 5Bd). In the case of the liver, Figure 5Be reveals
intense staining in normal hepatocytes. A nodule from an invasive
hepatocarcinoma displays a clear diminished expression (arrow in
Figure 5Bf). More intense immunoreactivity can be seen in normal
hepatocytes compressed by the tumour nodule (arrowhead). In
brain tissue, expression was negative for the normal tissue (Figure
5Bg) but positive in this case for an atypical meningioma (Figure
5Bh). Finally, in normal breast tissue, DESC1 expression was
restricted to glands and duct epithelium to a lesser extent. Figure
5Bi represents a reactive breast tissue with a very weak expression
surrounding a negative duct. With respect to tumours, a varied
panorama of negative (Figure 5Bj) and positive (Figures 5Bk and l)
DESC1 expression was observed (7 negative vs 12 positive cases).
Moreover, expression in breast depended on the tumour
histological type, being mainly restricted to ductal and lobular
variants, but other additional factors may also contribute as not all
of the ductal tumours analysed were positive. Additionally, two
cases of ductal carcinoma in situ showed increased expression with
respect to the corresponding infiltrating tumour. Data obtained
from this immunohistochemistry analysis suggest that both
up- and downregulation of DESC1 could be associated to cancer
progression.
DISCUSSION
Proteolytic activities have been traditionally associated with the
growth and expansion of different type of tumours. However,
different serine proteases have been found downregulated in
different types of human carcinomas. This is the case of DESC1,
the expression of which inversely correlates with progression of
head and neck tumours (Sedghizadeh et al, 2006). Our interest in
this type of neoplasias prompted us to investigate the implication
of DESC1 in cancer biology through the study of its activity, effect
on invasiveness of a known cell model and the analysis of its
expression in a variety of tumour tissues.
Common with most of the TTPS (Szabo et al, 2003) endogenous
targets for human DESC1 remain unresolved. However, the
production and purification of the recombinant catalytic
domain of this protease has revealed for the first time that it
exhibits a significant in vitro activity for substrates such as
fibronectin, gelatin or fibrinogen. The ability to degrade
extracellular matrix components has been observed in members
of the TTSP family such as matriptase (Lee et al, 2000) or
matriptase-2 (Velasco et al, 2002). This suggests that DESC1
could participate in the degradation of the extracellular matrix
that occurs in normal and pathological conditions, including
cancer. Likewise, DESC1 also shares with these two enzymes the
capability for pro-uPA activation, revealing the possibility that
DESC1 could participate in proteolytic cascades mediated by
activated uPA.
Our initial results prompted us to use the full-length DESC1 in
cell-based assays due to the fact that activity of the catalytic
domain expressed in a bacterial host does not accurately reflect the
enzyme activity in vivo. Moreover, the use of these types of assays
does not remove the possible influence of the ancillary domains on
the substrate specificity. We chose the dog kidney epithelial cell
line MDCK, which have been widely used to attempt to elucidate
the functional role in tumour processes of different proteins,
including membrane-associated metalloproteases (Kadono et al,
1998; Kang et al, 2000). After the selection of two clones that
expressed exogenous DESC1, we carried out three different types
of assays. First, we observed an increase in the migration and
motility properties of the clones that produce the protease, in a
scrape-wound migration assay respecting to the control cells.
Then, in matrigel-based invasion assays we found that MDCK/
DESC1 transfectants acquired an enhanced capacity to migrate and
extravasate the collagen matrix, adopting a branched and
elongated morphology. In a third type of assay, we showed of
these cells to form branching extension in a 3D collagen lattice.
The formation of this type of extensions represents a partial
epithelial–mesenchymal transition, which could finally induce
tubulogenesis (O’Brien et al, 2004). This is a phenotype relevant to
renal development and carcinogenesis, and takes place concurrent
with complex morphogenic processes that require cell prolifera-
tion and movement, rearrangements of the cytoskeleton and of the
cell–cell junctional complexes, and remodelling of the cell matrix
(Birchmeier et al, 2003). Results obtained in these assays evidence
for the first time that DESC1 is a serine protease that could be
involved in motility, cell growth and invasion processes.
Since DESC1 was identified as a gene downregulated in
carcinomas of the head and neck, and the data obtained in this
work indicate a possible involvement of this protease in the
tumorigenic process, we carried out an immunohistochemical
analysis of DESC1 expression in a variety of tissues of different
origin. Although we could confirm this downregulation in
larynx and pharynx tissues (not shown), the study revealed for
the first time overexpression of DESC1 in a variety of carcinomas
like kidney, brain and breast cancer. The up/downregulation
for a particular protease among different types of cancers has
been reported for other serine proteases, including some TTSPs.
Thus, loss of testisin expression has been found in testicular
tumorigenesis (Hooper et al, 1999), but its expression is associated
with advanced stages of ovarian cancer (Shigemasa et al,
2000). Matriptase is upregulated in prostate and cervical cancer
(Santin et al, 2003), but it is downregulated in advanced-stage
ovarian tumours (Tanimoto et al, 2005). Hepsin has been
described to promote cancer progression and metastasis in a
mouse model (Klezovitch et al, 2004), but it seems to inhibit
cell growth and invasion in prostate cancer cells (Srikantan
et al, 2002). Moreover, we can not rule out that DESC1
could likewise be involved in proteolytic cascades that would
include protease inhibitor as happens with matriptase
(Netzel-Arnett et al, 2006). In this regard, the mouse counterpart
of this protease, mDESC1, forms stable inhibitory complexes
with both plasminogen activator inhibitor-1 and protein C
inhibitor (Hobson et al, 2004). These observations raise new
intriguing questions about the role of DESC1 in normal and
pathological processes. To finally corroborate these data, further
exhaustive functional studies and analysis of its expression in
more tissues, including different histopathological parameters,
would be needed to assess the final balance of DESC1 expression
in each type of tissue. Moreover, we have shown in this study
that the generated antibodies do not recognise the three
serine protease domains of polyserase-1. However, it cannot be
ruled out that these antibodies could recognise other TTPS,
specially the closely related members of the HAT/DESC subfamily.
Additionally, the generation of the mouse lacking this
enzyme could contribute to shed light on the up- and down-
regulation of DESC1 in different tumours, and about its possible
involvement in complex proteolytic cascades.
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